A detailed history of Tower Research Capital LLC (Trc) transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,289 shares of CNTA stock, worth $39,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,289
Previous 1,298 76.35%
Holding current value
$39,279
Previous $11,000 227.27%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.58 - $16.99 $8,502 - $16,837
991 Added 76.35%
2,289 $36,000
Q2 2024

Aug 13, 2024

BUY
$8.04 - $11.87 $2,315 - $3,418
288 Added 28.51%
1,298 $11,000
Q1 2024

May 15, 2024

SELL
$6.73 - $12.2 $8,701 - $15,774
-1,293 Reduced 56.14%
1,010 $11,000
Q4 2023

Feb 13, 2024

SELL
$5.52 - $8.03 $4,211 - $6,126
-763 Reduced 24.89%
2,303 $18,000
Q3 2023

Nov 14, 2023

SELL
$6.01 - $8.24 $7,248 - $9,937
-1,206 Reduced 28.23%
3,066 $19,000
Q2 2023

Aug 14, 2023

SELL
$3.68 - $6.9 $15,831 - $29,683
-4,302 Reduced 50.17%
4,272 $26,000
Q1 2023

May 09, 2023

SELL
$3.03 - $4.0 $23,018 - $30,388
-7,597 Reduced 46.98%
8,574 $33,000
Q4 2022

Feb 10, 2023

BUY
$3.05 - $4.19 $33,226 - $45,645
10,894 Added 206.44%
16,171 $51,000
Q3 2022

Nov 10, 2022

BUY
$3.8 - $5.91 $14,440 - $22,458
3,800 Added 257.28%
5,277 $21,000
Q2 2022

Aug 15, 2022

BUY
$3.18 - $9.85 $737 - $2,285
232 Added 18.63%
1,477 $7,000
Q1 2022

May 12, 2022

BUY
$7.45 - $11.59 $2,346 - $3,650
315 Added 33.87%
1,245 $11,000
Q4 2021

Feb 14, 2022

BUY
$10.99 - $17.54 $8,912 - $14,224
811 Added 681.51%
930 $10,000
Q3 2021

Nov 15, 2021

SELL
$16.7 - $23.11 $15,998 - $22,139
-958 Reduced 88.95%
119 $2,000
Q2 2021

Aug 16, 2021

BUY
$21.71 - $25.66 $23,381 - $27,635
1,077 New
1,077 $24,000

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.62B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.